Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 531

The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.

Pathway Based Analysis of Mutation Data Is Efficient for Scoring Target Cancer Drugs

Open access
Zolotovskaia, Marianna A., Sorokin, Maxim I., Emelianova, Anna A., Borisov, Nikolay M., Kuzmin, Denis V., Borger, Pieter, Garazha, Andrew V., Buzdin, Anton A.·2019·Frontiers in Pharmacology

Abstract

Despite the significant achievements in chemotherapy, cancer remains one of the leading causes of death. Target therapy revolutionized this field, but efficiencies of target drugs show dramatic variation among individual patients. Personalization of target therapies remains, therefore, a challenge in oncology. Here, we proposed molecular pathway-based algorithm for scoring of target drugs using high throughput mutation data to personalize their clinical efficacies. This algorithm was validated on 3,800 exome mutation profiles from The Cancer Genome Atlas (TCGA) project for 128 target drugs. The output values termed Mutational Drug Scores (MDS) showed positive correlation with the published drug efficiencies in clinical trials. We also used MDS approach to simulate all known protein coding genes as the putative drug targets. The model used was built on the basis of 18,273 mutation profiles from COSMIC database for eight cancer types. We found that the MDS algorithm-predicted hits frequently coincide with those already used as targets of the existing cancer drugs, but several novel candidates can be considered promising for further developments. Our results evidence that the MDS is applicable to ranking of anticancer drugs and can be applied for the identification of novel molecular targets.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fphar.2019.00001

Cites

67 of 67 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 67 references

Research works printed but not linked: 8

  1. Buzdin, 2017, Activation of intracellular signaling pathways as a new type of biomarkers for selection of target anticancer drugs, J. Clin. Oncol., 35, e23142, 10.1200/JCO.2017.35.15_suppl.e23142 · doi:10.1200/jco.2017.35.15_suppl.e23142
  2. 2017, Leading Causes of Death and Numbers of Deaths, by Sex, Race, and Hispanic Origin: United States, 1980 and 2016
  3. Hornberger, 2005, Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer, Am. J. Manag. Care, 11, 313
  4. Ko, 2004, Targeting steroid hormone receptor pathways in the treatment of hormone dependent cancers, Curr. Pharm. Biotechnol., 5, 459, 10.2174/1389201043376616 · doi:10.2174/1389201043376616
  5. Petrov, 2017, Gene expression and molecular pathway activation signatures of MYCN-amplified neuroblastomas, Oncotarget, 8, 83768, 10.18632/oncotarget.19662 · doi:10.18632/oncotarget.19662
  6. Sorokin, 2018, Acquired resistance to tyrosine kinase inhibitors may be linked with the decreased sensitivity to X-ray irradiation, Oncotarget, 9, 5111, 10.18632/oncotarget.23700 · doi:10.18632/oncotarget.23700
  7. Wirsching, 2017, Temporary portal vein embolization is as efficient as permanent portal vein embolization in mice, Surgery, 162, 68, 10.1016/j.surg.2017.01.032 · doi:10.1016/j.surg.2017.01.032
  8. Zhu, 2007, Application of a new probabilistic model for mining implicit associated cancer genes from OMIM and medline, Cancer Inform., 2, 361, 10.1177/117693510600200025 · doi:10.1177/117693510600200025

Cited by

See all 531

Metadata

Authors
Zolotovskaia, M. A., Sorokin, M. I., Emelianova, A. A., Borisov, N. M., Kuzmin, D. V., Borger, P., Garazha, A. V., & Buzdin, A. A.
Venue
Frontiers in Pharmacology
Published
2019-01-23
Volume
10
Pages
1-1
ISSN
1663-9812 (ISSN-L)
OpenAlex
W2912929199
Cited by
531
References
67
FWCI
33.31
Type
journal article
Language
en
Open access
gold
Funders
  • Amazon Web Services
  • Microsoft
  • Russian Science Foundation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pathway Based Analysis of Mutation Data Is Efficient for Scoring Target Cancer Drugs. https://app.cochat.ai/papers/10.3389/fphar.2019.00001
The paper
Zolotovskaia, M. A., Sorokin, M. I., Emelianova, A. A., Borisov, N. M., Kuzmin, D. V., Borger, P., Garazha, A. V., & Buzdin, A. A. (2019). Pathway Based Analysis of Mutation Data Is Efficient for Scoring Target Cancer Drugs. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2019.00001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.